Efficacious too: The Hindu editorial on COVID-19 vaccine Covaxin
The restricted emergency use approval of Covaxin should now be revised Vaccine efficacy of 80.6% for Bharat Biotech’s Covaxin at the first interim analysis of phase-3 trials in India is indeed promising, though it took two months for the data to become available after the vaccine was approved for ‘restricted emergency use’ by the Indian drug regulator. The vaccine efficacy was measured based on symptomatic COVID-19 disease — mild, moderate or severe — two weeks after the second dose....
United Kingdom Astrazeneca Covishield Bharat Biotech Lancet Infectious Diseases While Covaxin Efficacious Too
Source: thehindu.com